虽然首日破发,但今年1月上市的肿瘤医院美中嘉和还是以80亿港元的市值让民营医院们看到了上市的盛景。 看到曙光的民营医院们前赴后继,一次申请上市不行再来一次。 佰泽医疗集团(下称“佰泽医疗”)就是再次递表港交所的一员,该公司此前在2024年4月26日递表,招银国际为独家保荐人。 和人们想象中“私立医院暴利”的固有印象不同,肿瘤医疗集团佰泽医疗持续亏损。更特别的是,佰泽医疗除了自身设立了一家医院...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.